Iifl Institutional Equities

Prabodh Agrawal of IIFL Institutional Equities has sharply reduced this year's Nifty earnings estimate to 8 percent from 16-17 percent at the beginning of the year

Market valuation not expensive at 16x earnings: IIFL

On the macro front, Prabodh Agrawal, president and head of research at IIFL Institutional Equities, continues to remain positive. He says even if GST implementation gets delayed by three months, it should not be an issue.

FY16 may see 18-19% earnings growth; like IT, cement: IIFL

Prabodh Agrawal of IIFL Institutional Equities says earnings will be the main driver of the market in the coming quarters. He is not betting on the market correcting 10%. He says cement, IT and auto sectors can see earnings upgrade over next 1-2 years.

Don't be distracted by Budget, keep buying market: IIFL

Prabodh Agrawal, president and head of research at IIFL Institutional Equities expects announcements pertaining to increase in spending in physical and social infrastructure in the Budget. He adds that this increase will partly be funded through increase in taxes – primarily indirect taxes.

Prefer HCL Technologies, Wipro: Sandeep Muthangi

Sandeep Muthangi, VP Research at IIFL Institutional Equities prefers prefer HCL Technologies and Wipro.

Infosys Results: IIFL sees co guiding to 12% growth in FY14

The debate on IT giant Infosys‘ results has multiple angles now, as it is likely to be a big trigger for all IT stocks. The company is going to announce its fourth quarter numbers on Friday. Sandeep Muthangi, Vice President - Research, IIFL Institutional Equities expects the company to give guidance of 12 percent odd growth for the next year.

Prefer Wipro, HCL Tech: Sandeep Muthangi

Sandeep Muthangi, Vice President - Research, IIFL Institutional Equities advises to prefer Wipro and HCL Tech over Infosys.

Expect 20% return in Sun Pharma: IIFL

Expect 20% return in Sun Pharma, says Bino Pathiparampil, IIFL Institutional Equities.

Cash flow improvement may lead to Glenmark re-rating: IIFL

Cash flow improvement may lead to Glenmark re-rating, says Bino Pathiparampil, IIFL Institutional Equities.

See 20% annual returns from Sun Pharma: IIFL Instl Eq

According to pharma analyst Bino Pathiparampil of IIFL Institutional Equities Sun Pharma could make USD 100 million from Doxil.

Expect 120 bps fall in Infosys' margins in Q3: IIFL Inst

In an interview with CNBC-TV18, Sandeep Muthangi of IIFL Institutional Equities spoke about his reading and outlook for Infosys, which will announce its third quarter numbers on Friday.

Tariff hike by telcos may drive revenue growth: IIFL

GV Giri, analyst at IIFL Institutional Equities believes the tariff hikes would not influence their sales volumes too much but, may result in some revenue growth given the low price elasticity.

Expect Infy to cut dollar revenue guidance to 7-8%: IIFL

Due to the weak global demand environment and adverse cross-currency movements, Sandeep Muthangi of IIFL Institutional Equities says IT major Infosys may cut its dollar revenue guidance for the year.

See SBI's Q4 slippages around Rs 6000-8000cr: IIFL Instl Eq

India's largest lender State Bank of India will declared its fourth quarter results today. In an interview to CNBC-TV18, Sampath Kumar of IIFL Institutional Equities says, he sees slippages anywhere between Rs 6,000-8,000 crore on gross basis.

Infosys Vs TCS? Pick Wipro, says IIFL

In the debate between TCS and Infosys, Sandeep Muthangi of IIFL tells CNBC-TV18 that he picks Wipro.

2012 likely to be tumultuous year for India: IIFL

2012 is likely to be yet another tumultuous and abrasive one for Indian equities, says H Nemkumar of IIFL Institutional Equities. The downdraft in business cycle led by deterioration in a number of macro economic variables may worsen.

IIFL disappointed with Union Bank, Oriental Bank Q2 results

Public sector banks have been a put-off this earnings season, with Union Bank and Oriental Bank of Commerce disappointing the most, says Sampath Kumar, senior research analyst at IIFL Institutional Equities.

Buy Mah Satyam, Dr Reddy's; sell SKS, BPCL: Brokerages

Bank of America Merrill Lynch maintains a 'buy' on Dr Reddy's, but has cut the price target to Rs 1,860. EPS estimates have been trimmed due to transition to IFRS financials, the Mexico facility import alert, and moderation of domestic formulations growth to 17% from 20%.

IIFL expects more downgrades to earnings estimates post Q1

With the possibility of further growth deceleration, the investment cycle showing no signs of pick-up, we expect more downgrades to the consensus earnings estimates post Q1.

FMCG cos rule out price cut post fall in raw material costs

FMCG firms are set to gain from decline in palm oil and other commodity prices, but most of them ruled out cutting prices of their products.